Elephas Biosciences

Elephas Biosciences develops elive, a live-tissue platform that prepares standard core-needle biopsies with an automated cutting instrument and gel, keeps the tissue alive, and measures changes in cytokine response after exposure to immunotherapies ex vivo. The company describes it as tumour-agnostic and sells it in three ways: the elive Test, which it says is available to select oncologists through an early access programme; services and platform components for pharmaceutical research and development; and research tools. Its site carries a 'For Research Use Only, not for use in diagnostic procedures' statement. It runs observational studies to measure how well elive predicts response to immune checkpoint inhibitors across solid tumours, including ELEPHAS-01 in non-small-cell lung cancer (NCT05478538), the ELEPHAS-02 basket study (NCT05520099), ELEPHAS-05 (NCT07327489) and a Mayo Clinic-sponsored study (NCT06349642). Its news page lists commercial partnerships with Neuberg Diagnostics in India and Invitrocue in Southeast Asia, and a peer-reviewed paper in Cell Reports Medicine.